Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

Matchpoint Therapeutics partners with Novartis to develop oral covalent inhibitors for inflammatory diseases, with potential ...

He joins a slew of Indians at the head of global firms both in the consumer space and in the tech world: Reports ...

Organizations that neglect kindness face significant consequences, including employee turnover, absenteeism, eroded trust, ...

The MoU, which aims to enhance cancer care, broaden cardiology collaboration, and promote medical training, has seen ...

Incyte Corp on Tuesday raised its annual sales forecast for blood cancer treatment Jakafi after robust demand helped the company surpass Wall Street estimates for second-quarter revenue and profit.

Novartis and Matchpoint Therapeutics have entered into a partnership worth $1bn to develop oral inhibitors for inflammatory ...

Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...